- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
ATL/Interspec merger approved
The merger of ultrasound vendorsATL and Interspec was approved this week by the shareholders ofboth companies. The companies announced the merger in February(SCAN 2/16/94). Under the terms of the merger, Interspec will become a whollyowned subsidiary
The merger of ultrasound vendorsATL and Interspec was approved this week by the shareholders ofboth companies. The companies announced the merger in February(SCAN 2/16/94).
Under the terms of the merger, Interspec will become a whollyowned subsidiary of ATL through an exchange of one share of Interspecstock for 0.413 shares of ATL stock. The acquisition creates anultrasound company with combined revenues of approximately $360million and an installed base of over 20,000 systems.
Interspec chief Edward Ray will continue as president of theAmbler, PA-based company and will join ATL's board of directors.ATL is based in Bothell, WA.
New Study Assesses Long-Term Outcomes of PSMA PET Use in PCa Recurrence Cases
October 24th 2024For patients with biochemical recurrence of prostate cancer, PSMA PET imaging may facilitate a 12.8 percent lower incidence of prostate cancer mortality in contrast to the combination of CT and bone scan, according to long-term outcome estimates from a new decision-analytic modeling study.
Can Diffusion MRI Predict Patient Response to Neoadjuvant Chemotherapy for Breast Cancer?
October 23rd 2024A model emphasizing time-dependent diffusion MRI was 15 percent more effective than apparent diffusion coefficient (ADC) measurements at predicting pathologic complete response to neoadjuvant chemotherapy for women with breast cancer, according to new research.
